Mylan May Have Overcharged Taxpayers by $1.27 Billion for EpiPen

``Under Medicaid, makers of brand-name drugs must provide deep discounts on their products. In October, Mylan said it reached a settlement with the U.S. to pay $465 million for misclassifying the drug as a generic product, which doesn't require the same discounts. Grassley has been critical of the October settlement, calling it too small.''